[HTML][HTML] Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative …
B Chun, J Pucilowska, SC Chang, I Kim… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Chemoimmunotherapy is a standard treatment for triple-negative breast cancer
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
[HTML][HTML] Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
In triple-negative breast cancer (TNBC), the benefit of combining chemotherapy with
checkpoint inhibitors is still not very clear. We utilize single-cell RNA-and ATAC-sequencing …
checkpoint inhibitors is still not very clear. We utilize single-cell RNA-and ATAC-sequencing …
Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).
1015 Background: Atezolizumab (anti-PD-L1) plus nab-paclitaxel was shown to improve
outcomes in mTBNC in a phase III clinical trial. Subjects were required to be> 12 months …
outcomes in mTBNC in a phase III clinical trial. Subjects were required to be> 12 months …
[HTML][HTML] Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
CA Egelston, W Guo, SE Yost, X Ge, JS Lee… - Cancer Immunology …, 2023 - Springer
Currently there is a limited understanding for the optimal combination of immune checkpoint
inhibitor and chemotherapy for patients with metastatic triple-negative breast cancer …
inhibitor and chemotherapy for patients with metastatic triple-negative breast cancer …
Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment
J Deng, A Thennavan, S Shah, E Bagdatlioglu… - Breast cancer research …, 2021 - Springer
Purpose Immunotherapy has recently been shown to improve outcomes for advanced PD-
L1-positive triple-negative breast cancer (TNBC) in the Impassion130 trial, leading to FDA …
L1-positive triple-negative breast cancer (TNBC) in the Impassion130 trial, leading to FDA …
[HTML][HTML] A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer
DB Page, J Pucilowska, B Chun, I Kim, K Sanchez… - NPJ Breast …, 2023 - nature.com
Chemoimmunotherapy with anti-programmed cell death 1/ligand 1 and cytotoxic
chemotherapy is a promising therapeutic modality for women with triple-negative breast …
chemotherapy is a promising therapeutic modality for women with triple-negative breast …
Abstract P2-09-03: Updated efficacy of first or second-line pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC) and …
DB Page, J Pucilowska, L Bennetts, I Kim, K Sanchez… - Cancer Research, 2019 - AACR
Abstract Background: In mTNBC, anti-PD-1/L1 monotherapy is most effective when
administered early in the course of disease, with recent trials demonstrating overall …
administered early in the course of disease, with recent trials demonstrating overall …
[HTML][HTML] Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
CK Anders, MG Woodcock… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Purpose Triple negative breast cancer (TNBC) is characterized by the presence of immune
cells in the tumor microenvironment, however, the response to single-agent immune …
cells in the tumor microenvironment, however, the response to single-agent immune …
First-line doublet chemotherapy for metastatic triple-negative breast cancer: circulating tumor cell analysis of the tnAcity trial
MC Liu, W Janni, V Georgoulias… - Cancer Management …, 2019 - Taylor & Francis
Purpose Circulating tumor cells (CTCs) are prognostic biomarkers in metastatic breast
cancer, but their role in predicting treatment outcomes in metastatic triple-negative breast …
cancer, but their role in predicting treatment outcomes in metastatic triple-negative breast …
[HTML][HTML] Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient …
TF He, SE Yost, PH Frankel, A Dagis, Y Cao, R Wang… - PLoS …, 2020 - journals.plos.org
The evolutionary changes in immune profiles of triple negative breast cancer (TNBC) are not
well understood, although it is known that immune checkpoint inhibitors have diminished …
well understood, although it is known that immune checkpoint inhibitors have diminished …
相关搜索
- breast cancer cell subsets
- breast cancer clonal repertoire
- metastatic tnbc pembrolizumab treatment
- metastatic tnbc nab paclitaxel
- breast cancer pembrolizumab and doxorubicin
- breast cancer paclitaxel taxol
- nab paclitaxel pembrolizumab treatment
- breast cancer flat dose
- breast cancer early treatment
- breast cancer patient prognosis
- pd l1 cell subsets
- breast cancer immunofluorescence analysis
- breast cancer doublet chemotherapy
- breast cancer pd l1
- breast cancer efficacy of pembrolizumab
- breast cancer priming dose